<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996498</url>
  </required_header>
  <id_info>
    <org_study_id>Hysteroscopic Myomectomy:</org_study_id>
    <nct_id>NCT04996498</nct_id>
  </id_info>
  <brief_title>Hemostatic Effect of Intrauterine Instillation of Oxytocin in Hysteroscopic Myomectomy</brief_title>
  <acronym>oxytocin</acronym>
  <official_title>Hemostatic Effect of Intrauterine Instillation of Oxytocin in Hysteroscopic Myomectomy: A Randomized Double Blinded Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams Maternity Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams Maternity Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no previous study on the hemostatic effect of intrauterine instillation of oxytocin&#xD;
      in hysteroscopic myomectomy. All previous studies focused on intravenous administration of&#xD;
      oxytocin.&#xD;
&#xD;
      This trial may modify the surgical environment in hysteroscopic myomectomy by decreasing&#xD;
      intraoperative bleeding to a degree that the amount of distention medium required for uterine&#xD;
      distention will be reduced with a better visibility and shorter operation time.&#xD;
&#xD;
      The standard treatment of symptomatic myomas is hysterectomy for women who have completed&#xD;
      childbearing period, and myomectomy for women who wish to preserve fertility hysteroscopic&#xD;
      myomectomy currently is the gold standard minimally invasive procedure for the management of&#xD;
      symptomatic submucous fibroids. Success of hysteroscopic myomectomy depends on good&#xD;
      visualization throughout the procedure, via the correct distending pressure, continuous&#xD;
      irrigation and the use of electrosurgery to control bleeding. Prolonged procedures that need&#xD;
      continuous irrigation under high pressure are associated with higher risk of excessive fluid&#xD;
      absorption and intravasation syndrome due to opened blood vessels within the myometrial,&#xD;
      moreover, the thermal damage of the healthy tissues is increased with the use of the&#xD;
      coagulation current.&#xD;
&#xD;
      Oxytocin receptors exist in the non-pregnant uterus but the concentration of the receptors is&#xD;
      much lower than in pregnancy. this is why the clinical use of oxytocin outside of pregnancy&#xD;
      is limited Oxytocin acts on oxytocin receptors in the myometrium and fibroid tissue leading&#xD;
      to uterine contraction and constriction of uterine vasculature due to uterine contraction and&#xD;
      vaso-constrictive effect of oxytocin thus reducing uterine perfusion and results in reducing&#xD;
      intraoperative bleeding.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be subjected to:&#xD;
&#xD;
        1. History taking: including personal history, menstrual and obstetric history, medical and&#xD;
           surgical history, medications.&#xD;
&#xD;
        2. Clinical examination; General and local with special concern about:&#xD;
&#xD;
             1. Size and position of the uterus&#xD;
&#xD;
             2. Transvaginal ultrasound to determine the number, size, location of fibroids and&#xD;
                evaluation of the myometrial free margin that is defined as the minimum thickness&#xD;
                between the outer edge of the fibroid and the inner edge of uterine serosa.&#xD;
&#xD;
        3. Laboratory evaluation: All participants will have routine blood tests: Complete Blood&#xD;
           Count (CBC), serum creatinine, viral markers, coagulation profile and liver function&#xD;
           tests.&#xD;
&#xD;
      Surgical procedure:&#xD;
&#xD;
        1. Office hysteroscopy will be performed the day before the procedure with the use of a 2-9&#xD;
           mm telescope with continuous-flow sheath (Hopkins II telescope 30 degrees: Karl storz)&#xD;
           to assess and confirm the fibroid location, its intracavitary portion and to exclude any&#xD;
           associated uterine pathology).&#xD;
&#xD;
        2. Hysteroscopy will be performed in the early proliferative phase (postmenstrual) in&#xD;
           dorsal lithotomy position under general anesthesia, cervical dilatation will be done&#xD;
           with Hegar dilators then resection of the submucous fibroid using monopolar resectoscope&#xD;
           using 1,5% glycine as a distension medium by single operator to avoid inter-observer&#xD;
           variability.&#xD;
&#xD;
        3. The intervention group (oxytocin group) will receive 10 IU of oxytocin for every 1000 ml&#xD;
           of the distending medium (1,5% Glycine). While in the control group a sterile&#xD;
           bacteriostatic water ampule in the same form will be added to every 1000 ml of the&#xD;
           distending medium (1,5% Glycine).&#xD;
&#xD;
        4. After completing the procedure, the surgeon will complete a record scale to document&#xD;
           estimated blood loss, rating the bleeding (0: no bleeding, I; mild bleeding, II:&#xD;
           moderate bleeding, III: severe bleeding, IV: severe bleeding with clots). Also will&#xD;
           document the clarity of visual field using 3 point likert scale as (poor, fair, good).&#xD;
&#xD;
        5. Post operative settings:&#xD;
&#xD;
             -  the duration of surgery and the volume of injected media will be calculated and&#xD;
                documented.&#xD;
&#xD;
             -  all patients will be subjected to postoperative hemoglobin 24 hours after the&#xD;
                procedure, any intraoperative or postoperative complications will be documented&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled double blinded clinical trial.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The allocation will be concealed in sealed, sequentially numbered, white envelopes which will be prepared by a statistician where the drug will be covered with adhesive tape and handed over to the data collector. each woman will collect the corresponding sealed envelope directly from the data collector and it will be opened just before application of the drug.&#xD;
the surgeon, the assistant and the nurse performing the procedure and the patient will be blinded to the medication drug which will be used inside the distention medium.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>the change in hemoglobin level 24 hours after the procedure surgery</measure>
    <time_frame>preoperative and 24 hour postoperative</time_frame>
    <description>the change of hemoglobin postoperative to know the effect of oxytocin compared to placebo in reducing blood loss.&#xD;
surgery compared to the pre-operative values to see if intrauterine instillation of oxytocin will reduce blood loss during hysteroscopic myomectomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of hematocrit level 24 hour after the procedure</measure>
    <time_frame>preoperative and 24 hour postoperative</time_frame>
    <description>a follow up CBC is done 24 hour after the procedure to see the difference in hematocrit and know about the blood loss intraoperative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the surgeon rating of intraoperative bleeding and the visual field quality of operative view,</measure>
    <time_frame>immediately postoperative</time_frame>
    <description>After completing the procedure, the surgeon will complete a record scale to document estimated blood loss, rating the bleeding (0: no bleeding, I; mild bleeding, II: moderate bleeding, III: severe bleeding, IV: severe bleeding with clots).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the duration of surgery, intraoperative</measure>
    <time_frame>immediately postoperative</time_frame>
    <description>Success of hysteroscopic myomectomy depends on good visualization throughout the procedure, so, if oxytocin decrease blood loss intraoperative , the operation time will be reduced .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative and postoperative complications</measure>
    <time_frame>intraoperative and within the first 24 hours postoperative</time_frame>
    <description>there are some operative complications as uterine perforation , cervical tear and fluid overload also, there is some adverse effects of oxytocin as arrythmia, nausea, vomiting , hypotension and abdominal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the surgeon rating the visual field</measure>
    <time_frame>immediately postoperative</time_frame>
    <description>After completing the procedure, the surgeon will document the clarity of visual field using 3 point scale as (poor, fair, good)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the volume of distension media used intraoperative</measure>
    <time_frame>immediately postoperative</time_frame>
    <description>glycine 1,5% is used as a distention media during procedure, each solution contain 1000 ml . counting the number of solution used intraoperative to calculate the amount of distension media used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Leiomyoma</condition>
  <arm_group>
    <arm_group_label>Group A (Oxytocin group):</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 women will undergo a hysteroscopic myomectomy with the use of 10 IU of oxytocin for every 1000 ml of the distending medium (1,5% Glycine ).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Placebo group):</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 women will undergo hysteroscopic myomectomy with the use of a sterile bacteriostatic water ampule in the distending medium (1,5% glycine).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>intrauterine Instillation of oxytocin in distention media used during Hysteroscopic Myomectomy</description>
    <arm_group_label>Group A (Oxytocin group):</arm_group_label>
    <other_name>syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sterile bacteriostatic water ampule</intervention_name>
    <description>a placebo drug similar in shape to oxytocin ampules</description>
    <arm_group_label>Group B (Placebo group):</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptomatic patient (Menorrhagia, recurrent pregnancy loss or infertility).&#xD;
&#xD;
          2. 1 or 2 submucous uterine myoma diagnosed by ultrasound with a diameter less than 4 cm&#xD;
&#xD;
          3. Myoma with FIGO 0 or 1.&#xD;
&#xD;
          4. Body mass index less than 35.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Active pelvic infection&#xD;
&#xD;
          3. history of bleeding disorder or patient on anti-coagulant.&#xD;
&#xD;
          4. hepatic and renal diseases.&#xD;
&#xD;
          5. history of ischemic heart disease.&#xD;
&#xD;
          6. Patients with uterine structural abnormality or uterine septum.&#xD;
&#xD;
          7. Present or history of cervical or uterine cancer.&#xD;
&#xD;
          8. Preoperative administration of gonadotropin-releasing hormone analogues or danazol.&#xD;
&#xD;
          9. Allergy to glycine.&#xD;
&#xD;
         10. Patients with hypercoagulopathy.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>amir Mahfouz, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>AinShams MH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir Mahfouz, Master</last_name>
    <phone>01013759260</phone>
    <email>amir.hamdy21@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahmoud Ghaleb, MD</last_name>
    <phone>01007212975</phone>
    <email>Mahmoudghaleb203050@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain shams university maternity hospital</name>
      <address>
        <city>Cairo</city>
        <state>Abbasia</state>
        <zip>11517</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Mahfouz, Master</last_name>
      <phone>01223266784</phone>
      <email>Amir.hamdy21@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mahmoud Ghaleb, MD</last_name>
      <phone>01007212975</phone>
      <email>Mahmoudghaleb203050@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1016/j.jmig.2011.09.005</url>
    <description>practice guidelines for the diagnosis and management of submucous leiomyomas. Journal of minimally invasive gynecology,</description>
  </link>
  <reference>
    <citation>Di Spiezio Sardo A, Mazzon I, Bramante S, Bettocchi S, Bifulco G, Guida M, Nappi C. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. Hum Reprod Update. 2008 Mar-Apr;14(2):101-19. Epub 2007 Dec 6. Review.</citation>
    <PMID>18063608</PMID>
  </reference>
  <reference>
    <citation>Vilos GA, Allaire C, Laberge PY, Leyland N; SPECIAL CONTRIBUTORS. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2015 Feb;37(2):157-178. doi: 10.1016/S1701-2163(15)30338-8.</citation>
    <PMID>25767949</PMID>
  </reference>
  <reference>
    <citation>Munro MG, Critchley HO, Broder MS, Fraser IS; FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011 Apr;113(1):3-13. doi: 10.1016/j.ijgo.2010.11.011. Epub 2011 Feb 22.</citation>
    <PMID>21345435</PMID>
  </reference>
  <reference>
    <citation>Maggi M, Magini A, Fiscella A, Giannini S, Fantoni G, Toffoletti F, Massi G, Serio M. Sex steroid modulation of neurohypophysial hormone receptors in human nonpregnant myometrium. J Clin Endocrinol Metab. 1992 Feb;74(2):385-92.</citation>
    <PMID>1309835</PMID>
  </reference>
  <reference>
    <citation>Atashkhoei S, Fakhari S, Pourfathi H, Bilehjani E, Garabaghi PM, Asiaei A. Effect of oxytocin infusion on reducing the blood loss during abdominal myomectomy: a double-blind randomised controlled trial. BJOG. 2017 Jan;124(2):292-298. doi: 10.1111/1471-0528.14416. Epub 2016 Nov 15.</citation>
    <PMID>27862855</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams Maternity Hospital</investigator_affiliation>
    <investigator_full_name>Amir Hamdy Abd El hady Mahfouz</investigator_full_name>
    <investigator_title>assistent lecturer</investigator_title>
  </responsible_party>
  <keyword>Hysteroscopic Myomectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

